Patients should be counseled to report severe abdominal pain immediately Gallbladder disease : Increased risk of cholelithiasis and cholecystitis, likely related to rapid weight loss Hypoglycemia : Risk is low when used alone but increases when combined with insulin or sulfonylureas Thyroid C-cell tumors : Based on rodent studies, these agents carry a boxed warning and are contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 Acute kidney injury : Can occur, particularly with dehydration from gastrointestinal side effects Diabetic retinopathy complications : Semaglutide may worsen diabetic retinopathy in patients with diabetes, particularly with rapid improvement in glucose control Severe gastrointestinal disease : Use with caution in patients with gastroparesis or severe gastrointestinal disease
In 2022 BPC-157 was also added to the WADA (World Anti-Doping Agency) prohibited list, paradoxically a confirmation that the molecule really works
Either everyone is wrong, or these compounds arent behaving the same way in the body and the second answer is closer to correct
For severe side effects, contact your provider immediately or seek emergency care if experiencing symptoms like severe abdominal pain or allergic reactions
Human preclinical data 4 show direct hypertrophic effects in human myotubes: IGF-1 increased myotube nuclei, fusion index, and myosin heavy chain content, demonstrating true cellular growth responses that underpin strength and size improvements seen with effective training
Injectable Microdosing: Whats the Difference
